Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kymera Therapeutics Inc (NQ: KYMR ) 37.94 +1.69 (+4.65%) Streaming Delayed Price Updated: 9:52 AM EDT, Jul 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Kymera Therapeutics Inc < Previous 1 2 3 Next > Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day July 09, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy July 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 June 20, 2024 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END Via FinancialNewsMedia Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 June 20, 2024 From FN Media Group LLC Via GlobeNewswire Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting June 14, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting June 01, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Participate in Upcoming June Investor Conferences May 29, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting May 23, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting May 22, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting May 14, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Participate in Upcoming May Investor Conferences May 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update May 02, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 April 25, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting April 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting March 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Participate in Upcoming March Investor Conferences February 28, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update February 22, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22 February 15, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference January 31, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs January 09, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares January 09, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Announces Pricing of $275 Million Public Offering January 05, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Announces Proposed Public Offering January 04, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases January 04, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 January 02, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4 December 13, 2023 Company to provide update on its emerging pipeline of high-value immunology programs From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting December 10, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi December 07, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine November 13, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting November 02, 2023 From Kymera Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
